發送短信 : Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

  _____    __   __    _____    __   __     _____  
 |__  //   \ \\/ //  / ____||  \ \\/ //   / ___// 
   / //     \ ` //  / //---`'   \ ` //    \___ \\ 
  / //__     | ||   \ \\___      | ||     /    // 
 /_____||    |_||    \_____||    |_||    /____//  
 `-----`     `-`'     `----`     `-`'   `-----`